An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection
Overview
- Phase
- Phase 4
- Intervention
- Mecobalamin IV Injection
- Conditions
- Peripheral Neuropathy
- Sponsor
- Eisai Co., Ltd.
- Enrollment
- 1072
- Locations
- 23
- Primary Endpoint
- Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
This is an open-label, randomized, multi-center clinical trial to evaluate the safety and efficacy in peripheral neuropathies patients treated with Mecobalamin Injection
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Group A: Diabetic Peripheral Neuropathy (IV)
Intervention: Mecobalamin IV Injection
Group B: Diabetic Peripheral Neuropathy (IM)
Intervention: Mecobalamin IM injection
Group C: Idiopathic Peripheral Neuropathy
Intervention: Mecobalamin IV or IM injection
Group D: Nutritional & Metabolic Peripheral Neuropathy
Intervention: Mecobalamin IV or IM injection
Group E: Compression Peripheral Neuropathy
Intervention: Mecobalamin IV or IM injection
Outcomes
Primary Outcomes
Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline
Time Frame: Baseline & End of Week 4
The TSS of peripheral neuropathy is used to score the intensity \& frequency of four symptoms in participants' feet/legs including: pain, burning sensation, numbness, and hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline (before treatment) scores were compared to scores after 4 weeks of treatment.
Rate of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline
Time Frame: Baseline and End of Week 4
TSS of peripheral neuropathy is used to score the intensity \& frequency of 4 symptoms in participants' feet/legs including: pain, burning sensation, numbness, hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline scores were compared to TSS decreasing rate after 4 weeks of treatment. Rate of TSS change = (TSS difference value/TSS before treatment)×100%.
Secondary Outcomes
- Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline(Baseline and End of Week 2)
- Rate of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline(Baseline and End of Week 2)
- Value of the Neural Injury Score of the Lower Limbs (NIS-LL) Compared to Baseline(Baseline and End of Week 4)
- Rate of the Neural Injury Score of the Lower Limbs (NIS-LL) Compared to Baseline(Baseline and End of Week 4)